Key Highlights: Implications: Viatris is selling up to 92 million Biocon shares (about 5.6% of the company) in a secondary sale, so Biocon gets no money from it; the deal is priced at a di...
Key Highlights: Implications: Emcure’s move to take Gennova to 100% ownership and fold it under the “One Emcure” framework tightens control over a strategically important biologi...
Key Highlights: Implications: The slump sale of Gennova’s small mRNA unit to Immunoscript for ₹139.5 crore effectively exits Emcure from a non-core, low-contribution bu...
Key Highlights: Implications: By reducing injections from 365 to 52 per year at near price parity, and potentially 20–25% lower annual treatment costs versus some analogue basals,&nbs...
Alkem Laboratories Limited is one of India’s leading pharmaceutical companies engaged in the development, manufacturing, and commercialization of branded generics, generic medicines, nutraceutic...
Syngene International Limited is one of Asia’s leading contract research, development, and manufacturing organizations (CRDMO), providing integrated scientific services to global pharmaceutical,...
Key Highlights: Implications: Mankind Pharma’s AI-led drug discovery partnership with Denovo Sciences strengthens its innovation agenda and adds another serious player to India’s eme...
Key Highlights: Implications: Pivot Path’s majority sale to an Ascent-led consortium effectively spins it out as an independent, PE-backed specialist, which should accelerate its growth in...
